Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity
暂无分享,去创建一个
[1] Gabriel L. Butterfield,et al. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. , 2014, Cancer research.
[2] Gabriel L. Butterfield,et al. microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites , 2014, Molecular Cancer Therapeutics.
[3] Teri E. Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing , 2013, Clinical pharmacology and therapeutics.
[4] Stefan Winter,et al. ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. , 2013, Pharmacogenomics.
[5] C. Lewis,et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity , 2013, British Journal of Cancer.
[6] A. V. van Kuilenburg,et al. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. , 2013, Pharmacogenomics.
[7] Kangsheng Wang,et al. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. , 2013, Cancer research.
[8] S. Krähenbühl,et al. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study , 2013, Cancer Chemotherapy and Pharmacology.
[9] J. Proost,et al. Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy , 2012, Clinical Pharmacokinetics.
[10] M. Crous-Bou,et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration , 2012, The Pharmacogenomics Journal.
[11] Ursula Amstutz,et al. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. , 2011, Pharmacogenomics.
[12] R. Wenstrup,et al. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. , 2011, Clinical colorectal cancer.
[13] C. Punt,et al. Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer , 2011, Clinical Cancer Research.
[14] H. McLeod,et al. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application , 2011, The Journal of pathology.
[15] A. V. van Kuilenburg,et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity , 2010, Human Genetics.
[16] U. Amstutz,et al. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. , 2009, Pharmacogenomics.
[17] A. Meindl,et al. Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients , 2008, PloS one.
[18] D. Pezet,et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] U. Hofmann,et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Tony Reiman,et al. Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity , 2007, Clinical Cancer Research.
[21] P. Soulié,et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance , 2006, Molecular Cancer Therapeutics.
[22] R. Diasio,et al. Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals , 2005, Clinical Cancer Research.
[23] K. Chansky,et al. Differences in toxicity between men and women treated with 5‐fluorouracil therapy for colorectal carcinoma , 2005, Cancer.
[24] Laurent Excoffier,et al. Arlequin (version 3.0): An integrated software package for population genetics data analysis , 2005, Evolutionary bioinformatics online.
[25] R. Diasio,et al. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. , 2004, Clinical colorectal cancer.
[26] Toshihiro Tanaka. The International HapMap Project , 2003, Nature.
[27] R. Diasio,et al. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. , 2002, Pharmacogenomics.
[28] Hans R Waterham,et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. , 2002, The Biochemical journal.
[29] S. Cha,et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Martin R. Johnson,et al. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] P. Vreken,et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] S. Antonarakis,et al. Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2000 .
[33] G. Boers,et al. Homocysteine, vitamin status and risk of vascular disease; effects of gender and menopausal status. European COMAC Group. , 1999, European heart journal.
[34] C. Rembold. Number needed to screen: development of a statistic for disease screening , 1998, BMJ.
[35] P. Vreken,et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. , 1997, European journal of cancer.
[36] S. Vollset,et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. , 1995, JAMA.
[37] O. Dassonville,et al. [Population study of dihydropyrimidine dehydrogenase in cancer patients]. , 1994, Bulletin du cancer.
[38] R. Diasio,et al. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. , 1993, Cancer research.
[39] Robert B. Diasio,et al. Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.
[40] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[41] J. Proost,et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. , 2012, Clinical pharmacokinetics.
[42] J. Novotný,et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. , 2009, Neoplasma.
[43] D. Jäger,et al. [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[44] P. Tam. The International HapMap Consortium. The International HapMap Project (Co-PI of Hong Kong Centre which responsible for 2.5% of genome) , 2003 .
[45] Elizabeth M. Smigielski,et al. dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..